Kanaph Therapeutics Inc
0082N0
Company Profile
Business description
Kanaph Therapeutics Inc is a biotech company dedicated to developing anticancer drugs and ophthalmic disease treatments based on human genome-based drug development technology. Its core technology lies in identifying novel targets with high unmet medical needs through the analysis of human genome data and disease-specific biological signatures, and in developing drugs of various modalities, including bispecific antibodies, antibody-drug conjugates (ADCs), and synthetic drugs, based on these findings. The groups pipeline products are KNP-101, KNP-301, KNP-502, KNP-503, KNP-504, and KNP-701.
Contact
3, Itaewon-ro 55ga-gil
5th Floor, Golden Nugget
Yongsan-gu
Hannam-dong
Seoul
KORT: +82 27989438
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
Stocks News & Analysis
stocks
Eli Lilly receives FDA approval to add another oral GLP-1 to market
Wide moat Eli Lilly receives FDA approval for obesity pill.
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Which of the 3 giant AI IPOs should you buy?
OpenAI, Anthropic, and Databricks are expected to go public this year at massive valuations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,774.90 | 124.80 | -1.40% |
| CAC 40 | 7,962.39 | 0.00 | 0.00% |
| DAX 40 | 23,168.08 | 130.81 | -0.56% |
| Dow JONES (US) | 46,504.67 | 61.07 | -0.13% |
| FTSE 100 | 10,436.29 | 71.50 | 0.69% |
| HKSE | 25,116.53 | 177.50 | -0.70% |
| NASDAQ | 21,879.18 | 38.23 | 0.18% |
| Nikkei 225 | 53,123.49 | 660.22 | 1.26% |
| NZX 50 Index | 12,902.15 | 76.28 | 0.59% |
| S&P 500 | 6,582.69 | 7.37 | 0.11% |
| S&P/ASX 200 | 8,579.50 | 105.50 | -1.21% |
| SSE Composite Index | 3,919.29 | 29.27 | -0.74% |